Analyst Price Targets — ASMB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 20, 2025 12:09 pm | Salim Syed | Mizuho Securities | $40.00 | $39.00 | TheFly | Assembly Biosciences price target raised to $40 from $29 at Mizuho |
| September 24, 2025 8:29 am | Roy Buchanan | JMP Securities | $38.00 | $25.90 | TheFly | Assembly Biosciences initiated with an Outperform at Citizens JMP |
| September 24, 2024 6:41 am | Salim Syed | Mizuho Securities | $36.00 | $16.26 | StreetInsider | Mizuho Reiterates Outperform Rating on Assembly Biosciences (ASMB) |
| September 20, 2024 3:30 am | Dennis Ding | Jefferies | $35.00 | $18.50 | StreetInsider | Jefferies Upgrades Assembly Biosciences (ASMB) to Buy |
Latest News for ASMB
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase…
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to
Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HDV candidate ABI-6250 are expected to initiate by end of 2026, with interim catalysts ahead. ABI-6250 aims to be the first oral HDV therapy, addressing an unmet need with positive phase 1a data and a favorable safety…
Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to a loss of $1.57 per share a year ago.
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 –
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASMB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.